News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
News Kite and Fosun appoint leader for CAR-T debut in China But rival Juno finally gives up on lead therapy.
Views & Analysis Interview: Vas Narasimhan on Novartis' goal to lead in CAR-T... Novartis’ head of drug development talks about its stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions about safety, manufacturing and cost versus clinical value remain
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
Events Partner Content Viral Safety - 25-27 April 2017 - Amserdam, The Netherlands Viral Safety conference
News EU green light for Novartis combo in lung cancer Tafinlar and Mekinist looks set for approval in BRAF V600 lung cancer
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
